Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/3/2020
SIETES contiene 92954 citas

 
 
 1 a 20 de 122 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 2016;375:296-7. [Ref.ID 100503]
2.Tiene citas relacionadas Cita con resumen
Offley W. Should flu vaccination be mandatory for healthcare workers?. BMJ 2013;347:18-9. [Ref.ID 96700]
3.
Macartney K, Chiu C, Georgousakis M, Brotherton JML. Safety of human papillomavirus vaccines: a review. Drug Saf 2013;36:393-412. [Ref.ID 95663]
4.Tiene citas relacionadas Cita con resumen
Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM, Vellozzi C, Yih WK, Gellin B, Lurie N, the H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013;381:1461-8. [Ref.ID 95302]
5.Tiene citas relacionadas
Poland GA, Poland CM, Howe CL. Influenza vaccine and Guillain-Barré syndrome: making informed decisions. Lancet 2013;381:1437-9. [Ref.ID 95299]
6. Cita con resumen
Yuki N, Hartung H-P. Medical progress: Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304. [Ref.ID 93212]
7. Cita con resumen
Verity C, Stellitano L, Winstone AM, Andrews N, Stowe J, Miller E. Guillain-Barré syndrome and H1N1 influenza vaccine in UK children. Lancet 2011;378:1545-6. [Ref.ID 91770]
8.Tiene citas relacionadas
Wu J, Lu M, Deng Y. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. Author/editor response. N Engl J Med 2011;364:1182. [Ref.ID 90521]
9.Tiene citas relacionadas
Mu XD. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2011;364:1181. [Ref.ID 90520]
10.Tiene citas relacionadas
Kelley NS, Osterholm MT, Belongia EA. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2011;364:1181. [Ref.ID 90519]
11.Tiene citas relacionadas Cita con resumen
Liang X-F, Liu D-W, Li K-L, Wu WD, Zhu BP, Wang HQ, Luo H-M, Cao L-S, Zheng JS, Yin DP, Cao L, Wu BB, Bao H-H, Xu DS, Yang WZ, Wang Y. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011;364:638-47. [Ref.ID 90215]
12.Tiene citas relacionadas Cita con resumen
Wu J, Lu L, Miao L, Gao T, Ji W, Liu D, Ma R, Yu R, Zhangzhu J, Liu W, Zeng Y, Li X, Zhang X, Pang X, Deng Y. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010;363:2416-23. [Ref.ID 89800]
13. Cita con resumen
López Nieto M, Gómez Garrido J, Losa Palacios A, Águila Manso G. Síndrome de Guillain-Barré secundario a vacunación de gripe H1N1. Rev Clin Esp 2010;210:485-6. [Ref.ID 89222]
14. Cita con resumen
Bryan P, Seabroke S, Davies C. H1N1 vaccine safety: real-time surveillance in the UK. Lancet 2010;376:417-8. [Ref.ID 89074]
15. Cita con resumen
Anónimo. Reacciones adversas asociadas a las vacunas pandémicas frente a la gripe A (H1N1). Boletín de la Tarjeta Amarilla. Centro Regional de Farmacovigilancia de Castilla y León 2010;29:2-4. [Ref.ID 88865]
16. Cita con resumen
Prothro C, Kudish K, Fiellin M, Meek J, Tellman N, Milewski M, Hogan B, Holtzman C, Danila R, Dunning L, Lynfield R, Scherzinger K, Connor W, Baumbach J, Giambrone GP, Zansky SM, Smith PF, Thomas A, Mosites E, Kirschke D, Viray M, Lewis P, Sejvar J, Baughman A, Vellozzi C, Fridkin S, Conner S, Morgan O, Lu P, Furlow C, Singleton JA, Hale CR, Kattan J, Murphree R, Oh JY, Wise M. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine --- United States, 2009--2010. MMWR Morb Mortal Wkly Rep 2010;59:1-5. [Ref.ID 88533]
17.Tiene citas relacionadas Cita con resumen
Huang WT, Chuang J-H, Kuo SH-S. Monitoring the safety of pandemic H1N1 vaccine. Lancet 2010;375:1164. [Ref.ID 88235]
18.Tiene citas relacionadas Cita con resumen
DeStefano F, Tokars J. H1N1 vaccine safety monitoring: beyond background rates. Lancet 2010;375:1146-7. [Ref.ID 88231]
19. Cita con resumen
Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22. [Ref.ID 87323]
20. Cita con resumen
Seleccionar todas
 
 1 a 20 de 122 siguiente >>